Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIS-Program neoadjuvant immunotherapy in early-stage breast cancer
2024-512826-26-00Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab, bevacizumab, pertuzumab and trastuzumab in triple-negative breast cancer (TNBC) and breast cancer (2 arms), sponsored by Gustave Roussy. Primary endpoint: Two-fold increase in GzmB+ CD8+ T cell levels from baseline to post-treatment window in biopsies. Started Sep 2024; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2024-512826-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512826-26-00.